pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·57m ago·1 min read
save

Two more biotechs, Marea and North Immunology, do reverse mergers

The reverse merger party is still buzzing. This time, it's a cardio and endocrine startup with two drugs in Phase 2 and a biotech working on a long-acting immunology and inflammation (I&I) drug. Mid-stage Marea ...

Sep 17, 2026·read at Endpoints ↗

September 17, 2026 11:35 AM EDT StartupsDeals Re­verse merg­er run ex­tends as Marea, North Im­munol­o­gy line up deals with $405M in back­ing Kyle LaHucik Biotech Correspondent The re­verse merg­er par­ty is still buzzing. This time, it’s a car­dio and en­docrine start­up with two drugs in Phase 2 and a biotech work­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
86 words · retrieved 2m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoA Parkinson's biotech debut, fundraising campaign and licensing dealEndpoints
  • 1h agoWhat's next for Medicare's health tech pilotEndpoints
  • 1h agoThe Endpoints 11: How we picked 2026's most exciting biotech startupsEndpoints
  • 1h agoRoche eyes label expansion for Lunsumio after confirmatory lymphoma trial winEndpoints
  • 3h agoGeneral Catalyst details tech partnerships at Summa HealthEndpoints